Table 3.
Data on adverse outcomes and adverse events by intervention group in the followed hospitalised patients
| IMT group (N = 31) | Sham IMT group (N = 34) | p value | RR (CI 95%) | NNT | |
|---|---|---|---|---|---|
| Hospital LOS (days) [mean ± SD] | 35.3 ± 2.7 | 41.8 ± 3.5 | < 0.01 | - | - |
| Patients intubated [n (%)] | 4 (15.3) | 12 (42.8) | 0.03 | 0.36 (0.27–0.97) | 3.64 |
| Hospital mortality [n (%)] | 2 (6.4) | 10 (29.4) | 0.04 | 0.23 (0.2–0.94) | 8.60 |
| Muscle weakness [n (%)] | 2 (7.7) | 6 (21.4) | 0.02 | 0.36 (0.19–0.98) | 7.28 |
| Adverse eventsa [n (%)] | 21 (1.6) | 22 (1.6) | 0.84 | 1.11 (0.39–3.22) | - |
| Cephalalgia | 6 (0.5) | 7 (0.5) | - | - | - |
| Dyspnoea | 6 (0.5) | 6 (0.4) | - | - | - |
| Pain | 5 (0.3) | 4 (0.3) | - | - | - |
| Hypertension | 4 (0.2) | 3 (0.2) | - | - | - |
| Dizziness | 1 (0.1) | 2 (0.2) | - | - | - |
CI confidence interval, IMT group inspiratory muscle training group, Sham IMT group sham inspiratory muscle training group, LOS length of stay, RR relative risk, NNT number needed to treat, SD standard deviation
a2655 interventions: 1285 for the inspiratory muscle training group and 1370 for the
sham inspiratory muscle training group